Capastat

Generic Name: Capreomycin sulfate
Product Name: Capastat

Indication

Used in the treatment of pulmonary infections caused by capreomycin susceptible strains of M.tuberculosis in conjunction with other anti-tuberculosis agents. Capreomycin is a second line agent, for use when the primary agents (isoniazid, rifampicin, ethambutol, aminosalicylic acid and streptomycin) have proven ineffective or toxic.

Action

Microbiology

Capreomycin is active against Mycobacterium tuberculosis.

Pharmacokinetics

Following intramuscular injection peak serum levels are reached 1-2 hours after administration, and half of the dose in excreted in urine, virtually unchanged, within 12 hours.

Dose advice

Usual dose: 1 g intramuscularly daily, for 60-120 days, then 1 g intramuscular 2-3 times weekly.
Impaired renal function. To maintain a steady state capreomycin level of 10 microgram/mL dosage adjustment is advised in patients with reduced renal function.
Creatinine clearance < 10 mL/min: 2.43 mg/kg every 24 hours.
Creatinine clearance 10-29 mL/min: 3.58 mg/kg, every 24 hours.Creatinine clearance 30-39 mL/min: 4.72 mg/kg, every 24 hours.Creatinine clearance 40-49 mL/min: 5.87 mg/kg, every 24 hours.
Creatinine clearance 50-59 mL/min: 7.01 mg/kg, every 24 hours.

Use in pregnancy

(Category C) Capreomycin should only be used in pregnant women if the potential benefit outweighs the risk.

Use in lactation

The presence of capreomycin in breastmilk is not known, and caution should be exercised in breastfeeding women.

Use in children

Safety and efficacy has not been determined.